Eight Weeks on Fluoxetine and No Better: Next Steps for a 15-Year-Old With SSRI-Resistant Depression and Passive Suicidal Thoughts, Using the TADS and TORDIA Trials and the Boxed Warning Data
[Student Name]
University of Phoenix
PMH/505: Psychiatric Management Of Children And Adolescents
Week 4 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Jordan, 15, was started on fluoxetine 20 mg by his pediatrician eight weeks ago for depression, without therapy, because of a waitlist. His dose was increased to 40 mg at week four. He remains withdrawn, sleeps 11 hours, has quit soccer and says, "Sometimes I think it would be easier if I didn't wake up." His Children's Depression Rating Scale-Revised score has barely changed. His parents ask whether the medication is making things worse. What follows describes the assessment and next steps.
Suicide Risk First
His passive death wish requires structured assessment before anything else. Jordan denies active suicidal thoughts, plans, intent or past attempts. He has no access to firearms; his parents confirm this. He has no substance use. He can name reasons to live: his younger sister and his dog. He agrees to a safety plan, which is written with him and his parents today, including removal of stored medications from the home, with his parents controlling his fluoxetine supply.
Rethinking the Diagnosis
Before changing treatment, it is worth checking that the diagnosis and the dose are right. Jordan took his medication consistently, according to his parents and pharmacy records. His thyroid function is normal. He has no history of hypomania that would suggest bipolar disorder, though his sleeping 11 hours raises the question; there is no family history of bipolar disorder either. Bullying was considered, and he denies it. The main stressor he names is his parents' frequent arguing about money since his father's layoff.
Adolescent Interview
Jordan is interviewed alone for part of each visit. Adolescents often disclose suicidal thoughts, substance use and conflicts only when parents are out of the room. He reports that he feels like a burden to his parents because of the family's financial stress, a theme that therapy can address.
What the First Step Should Have Been
March et al. (2004), reporting the Treatment for Adolescents With Depression Study, randomly assigned 439 adolescents with major depression to fluoxetine, CBT, their combination or placebo. Response rates were 71.0% with the combination, 60.6% with fluoxetine alone, 43.2% with CBT alone and 34.8% with placebo, and suicidal thinking improved in all groups, most with the combination. The authors concluded that fluoxetine with CBT offered the most favorable balance of benefit and risk. Jordan received fluoxetine alone, so therapy is an obvious missing component.
Is the Medication Making Things Worse?
Hammad et al. (2006), analyzing 24 pediatric antidepressant trials submitted to the FDA, found no completed suicides but a modestly increased risk of suicidal ideation and behavior, with an overall risk ratio of 1.95 across all drugs and indications and a risk difference of about 2%. This is the basis for the boxed warning. I explain to Jordan's parents that his passive thoughts predate the medication, according to his history, and have not worsened since it started, but that any new or increasing suicidal thoughts, agitation or unusual behavior must be reported at once.
The warning is about a small risk worth watching, not a reason to leave depression untreated.
The Second Step
Brent et al. (2008), in the TORDIA trial, randomly assigned 334 adolescents whose depression had not responded to two months of an SSRI to switch to another SSRI or to venlafaxine, with or without CBT. CBT plus a medication switch produced a higher response rate, 54.8%, than a switch alone, 40.5%. Venlafaxine and a second SSRI produced similar response rates, but venlafaxine caused more increases in blood pressure and pulse and more skin problems.
The Plan
Jordan will switch from fluoxetine to sertraline, cross-tapering over two weeks, and start weekly CBT with a therapist who has an opening. CBT will focus on behavioral activation, including returning to one activity he enjoyed, and on identifying and challenging hopeless thinking. His parents will attend some sessions to learn how to support him without pressure.
Why Sertraline
Sertraline has pediatric trial evidence in depression and anxiety, a manageable side effect profile and a lower potential for drug interactions than some other SSRIs. Starting at 50 mg while tapering fluoxetine, and increasing to 100 mg if needed, is a reasonable schedule. Fluoxetine's long half-life allows a relatively smooth transition.
The Family Stressor
With permission, a family session addresses the tension at home. His parents had not known that Jordan blamed himself for the family's money worries. They reassure him and agree to keep financial discussions private.
Why Not Venlafaxine
The TORDIA trial found that a second SSRI was as effective as venlafaxine with fewer adverse effects (Brent et al., 2008). A second SSRI is the better choice.
Screening Tools
The PHQ-9 modified for adolescents is completed at every visit alongside the CDRS-R, because a quick self-report catches changes between clinician ratings. Item nine, on thoughts of death, triggers a full risk review whenever it is endorsed. His parents also complete a brief rating of his mood and functioning at home.
Monitoring
Visits are weekly for the first month, then every two weeks. Suicidal thoughts are assessed at each visit with a structured screen. The CDRS-R is repeated at four and eight weeks, and any rise in agitation or insomnia after the switch prompts an earlier visit.
If the Second Step Fails
If Jordan has not responded after eight to twelve weeks of sertraline and CBT, the next options include switching to another antidepressant, adding interpersonal therapy or considering augmentation with specialist consultation. Referral to an intensive outpatient program is considered if his functioning declines or his suicidal thinking increases.
Sleep and Routine
His 11 hours of sleep and late rising disrupt school mornings. A regular wake time, even on weekends, and morning light exposure help restore his rhythm and support mood.
School
With permission, the school counselor is informed that Jordan is in treatment and may need flexibility with deadlines for a few weeks.
Behavioral Activation
Depressed adolescents withdraw from activities that once gave them pleasure, which deepens their mood. Jordan agrees to rejoin soccer practice twice a week, even if he does not feel like it, and to spend one evening a week with a friend. Mood often follows action rather than preceding it.
Confidentiality
Jordan is told that what he says in sessions stays private, except when his safety is at risk, in which case his parents will be informed. He is told this at the first private interview, so he can decide what to share with full knowledge of the limits.
Conclusion
Jordan's depression did not respond to fluoxetine alone, the less effective first step according to TADS. The boxed warning reflects a modest increase in suicidality that calls for monitoring, not avoiding treatment. The TORDIA trial supports adding CBT and switching to a second SSRI, and his plan does both, with safety planning and close monitoring at every step.
References
Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., Birmaher, B., Ryan, N., Kennard, B., Hughes, C., DeBar, L., McCracken, J., Strober, M., Suddath, R., Spirito, A., . . . Zelazny, J. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA, 299(8), 901-913. https://doi.org/10.1001/jama.299.8.901
Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332-339. https://doi.org/10.1001/archpsyc.63.3.332
March, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., Burns, B., Domino, M., McNulty, S., Vitiello, B., & Severe, J. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292(7), 807-820. https://doi.org/10.1001/jama.292.7.807
How this PMH 505 Week 4 example is structured
The PMH/505 Week 4 work usually covers adolescent depression, suicide risk and safety planning. This paper shows how evidence guides both the first and second steps of treatment, while suicide risk is assessed and managed at every stage. Students search this week as PMH 505 Week 4, PMH505 Wk 4 or PMH/505 Wk 4; all three are the same assignment.
PMH/505 Week 4 questions, answered
What does PMH/505 Week 4 usually ask for?
Many sections ask students to assess and treat depression in an adolescent, including suicide risk assessment, safety planning, psychotherapy and antidepressant use with the boxed warning.
What did the TADS trial show?
In adolescents with major depression, fluoxetine combined with CBT had the highest response rate, about 71%, compared with 61% for fluoxetine alone, 43% for CBT alone and 35% for placebo.
What should be done if an adolescent does not respond to an SSRI?
In the TORDIA trial, adding CBT to a medication switch improved response rates, and switching to a second SSRI worked as well as switching to venlafaxine with fewer side effects.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.